Bulletin
Investor Alert

New York Markets Close in:

Incyte Corp.

NAS: INCY

GO
/marketstate/country/us

Market open

/zigman2/quotes/204510994/composite

$

78.07

Change

+1.95 +2.56%

Volume

Volume 165,431

Oct 14, 2019, 11:39 a.m.

Real time quotes

/zigman2/quotes/204510994/composite

Previous close

$ 76.12

$ 78.07

Change

+1.95 +2.56%

Day low

Day high

$76.26

$78.30

Open
Open: 76.39

52 week low

52 week high

$57.00

$89.30

Open

Market cap

$16.37B

Average volume

1.14M

P/E ratio

55.26

Rev. per Employee

$1.38M

EPS

1.41

Dividend

N/A

Div yield

N/A

Ex dividend date

N/A

Compare:
Indexes
  • Dow(INDU) INDU
  • Nasdaq (COMP) COMP
  • S&P 500 (SPX) SPX
  • Global Dow (GDOW) GDOW
1d
5d
3m
6m
1y
3y
5y
/news/latest/company/us/incy

MarketWatch News on INCY

  1. European Conference Highlights Cancer-Drug Developments

    7:00 a.m. Oct. 3, 2019

    - Barron's Online

  2. The 3 Best Health-Care Stocks This Month. And the Worst

    6:00 a.m. Sept. 30, 2019

    - Barron's Online

  3. A Big Cancer Conference Could Yield Breakthroughs

    7:10 a.m. Oct. 1, 2019

    - Barron's Online

  4. Incyte upgraded to outperform from perform at Oppenheimer

    8:31 a.m. Sept. 5, 2019

    - Tomi Kilgore

  5. Incyte stock price target raised to $100 from $85 at Oppenheimer

    8:31 a.m. Sept. 5, 2019

    - Tomi Kilgore

  6. 3 stocks that can make you money despite a trade war or recession

    7:31 a.m. July 21, 2019

    - Philip van Doorn

  7. Incyte enters license deal with Zai Lab for commercialization of Incyte's cancer treatment in China

    7:35 a.m. July 2, 2019

    - Tomi Kilgore

  8. The Dow Is Treading Lightly Ahead of a Possible Fed Rate Cut

    5:50 p.m. June 17, 2019

    - Barron's Online

  9. What to expect when Merck reports earnings Tuesday

    1:41 p.m. April 29, 2019

    - Sarah Toy

  10. Health-care drama has now spread to biopharma stocks

    9:27 a.m. April 19, 2019

    - Sarah Toy

  11. Incyte started at hold with $82 stock price target at Stifel Nicolaus

    7:26 a.m. April 11, 2019

    - Tomi Kilgore

  12. Loading more headlines...
/news/nonmarketwatch/company/us/incy

Other News on INCY

  1. Incyte's ruxolitinib cream shows sustained benefit in mid-stage vitiligo study

    7:28 a.m. Today

    - Seeking Alpha

  2. Mizuho Securities Maintains Their Buy Rating on Incyte Corp (INCY)

    6:26 a.m. Today

    - SmarterAnalyst

  3. Seattle Genetics Begins Phase III Study on Tucatinib Combo

    12:40 p.m. Oct. 11, 2019

    - Zacks.com

  4. 10 Great Biotech Stocks to Buy in Q4

    12:17 p.m. Oct. 7, 2019

    - InvestorPlace.com

  5. Incyte Sees Hammer Chart Pattern: Time to Buy?

    5:28 a.m. Oct. 4, 2019

    - Zacks.com

  6. Incyte Corp (INCY) Receives a Buy from Mizuho Securities

    4:11 p.m. Oct. 2, 2019

    - SmarterAnalyst

  7. Incyte Corp: Maybe The Next Netflix

    1:52 p.m. Sept. 30, 2019

    - Seeking Alpha

  8. Incyte (INCY) Presents At ESMO Congress 2019 - Slideshow

    12:59 p.m. Sept. 30, 2019

    - Seeking Alpha

  9. Incyte Corp (INCY) Gets a Buy Rating from Cowen & Co.

    1:39 p.m. Sept. 27, 2019

    - SmarterAnalyst

  10. Incyte (INCY) Stock Up 16% YTD on Strong Jakafi Performance

    10:47 a.m. Sept. 27, 2019

    - Zacks.com

  11. Incyte Treats First Patient in Phase III Vitiligo Study

    9:02 a.m. Sept. 26, 2019

    - Zacks.com

  12. Loading more headlines...
/news/pressrelease/company/us/incy

Press Releases on INCY

  1. Incyte to Report Third Quarter Financial Results

    8:00 a.m. Oct. 10, 2019

    - BusinessWire - BZX

  2. Loading more headlines...

Rates »

Trending Tickers
  • /quotes/zigman/17636479/composite VUZI+15.60%
  • /quotes/zigman/237947/composite JCP-5.83%
  • /quotes/zigman/59392505/composite NUGT-2.93%
  • /quotes/zigman/59386294/composite JNUG-5.94%
  • /quotes/zigman/65801738/composite TLT+1.11%
X
Powered by StockTwits
Link to MarketWatch's Slice.